What if one of healthcare’s most complex administrative challenges—revenue cycle management—was reframed as a data science problem? In this episode, Malinka Walaliyadde, co-founder and CEO of Akasa, joins Julie Yoo to unpack how large language models (LLMs) are transforming the way hospitals get paid by automating highly nuanced coding and billing workflows. Drawing comparisons to self-driving cars and fintech infrastructure, Malinka reveals how AI is finally making it possible to extract simplicity from a sea of clinical complexity. From a strategic focus on inpatient medical coding to the company’s deeply embedded partnerships with leading health systems like the Cleveland Clinic, he outlines why being “mile deep” matters more than ever. This conversation offers practical insights on market entry, model development, and workforce transformation—underscoring why AI for revenue cycle is not just a hot space, but an enduring opportunity. For healthcare entrepreneurs seeking to build at the intersection of AI, enterprise sales, and operational excellence, this episode is essential listening.
Resources:
Stay Updated:
Subscribe on your favorite podcast app here.
“Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.”
Sign up for our bio + health newsletter to get the latest take from us on the future of biology, technology, and care delivery.
Check your inbox for a welcome note.
Malinka Walaliyadde LinkedIn
Julie Yoo is a general partner on the Bio + Health team at Andreessen Horowitz, focused on transforming how we access, pay for, and experience healthcare.
Olivia Webb is the editorial lead, healthcare, on the Bio + Health team.
Kris Tatiossian is the content lead, life sciences, on the Bio + Health team.
The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.
This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.
Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.
Biology and the state of healthcare are undergoing radical shifts. Raising Health delves into dialogues with scientists, technologists, founders, builders, leaders, and visionaries as they explore how AI, engineering, and technology elevate health to new heights and create a system of enduring health for all.